Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 151, 45-52
- https://doi.org/10.1016/j.ejpb.2020.03.012
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- In Vitro–In Vivo Correlation of Efavirenz Tablets Using GastroPlus®AAPS PharmSciTech, 2013
- Developing In Vitro–In Vivo Correlation of Risperidone Immediate Release TabletAAPS PharmSciTech, 2012
- Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo dataJournal of Pharmaceutical and Biomedical Analysis, 2011
- In vitro–in vivo correlation for nevirapine extended release tabletsBiopharmaceutics & Drug Disposition, 2009
- Clinical Relevance of Dissolution Testing in Quality by DesignThe AAPS Journal, 2008
- IV-IVC considerations in the development of immediate-release oral dosage formJournal of Pharmaceutical Sciences, 2005
- Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong BasesJournal of Pharmaceutical Sciences, 2005
- In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution mediaEuropean Journal of Pharmaceutical Sciences, 2005
- In vitro–in vivo correlation (IVIVC) models for metformin after administration of modified‐release (MR) oral dosage forms to healthy human volunteersJournal of Pharmaceutical Sciences, 2001
- In vitro–in vivo correlations for lipophilic, poorly water-soluble drugsEuropean Journal of Pharmaceutical Sciences, 2000